31st week of 2019 patent applcation highlights part 9 |
Patent application number | Title | Published |
20190231641 | CPR CHEST COMPRESSION MACHINE STOPPING TO DETECT PATIENT RECOVERY - Embodiments of the present concept are directed to CPR chest compression machines that include a sensor to detect a parameter about a patient, such as an indication of patient recovery, and include a processor that determines whether to cease series of successive compressions on the patient in response to the detected parameter. | 2019-08-01 |
20190231642 | Airway Bridge and Method for Using the Same - A device and method for performing cardiopulmonary resuscitation (CPR) on a patient. The device is an extendable airway bridge which is initially in a collapsed or storage configuration. Upon use, the airway bridge is unfolded and then fixed into an operating configuration by locking at least one incline portion and at least one vertical portion into a static position. The structural strength of the airway bridge is then increased by manipulating a support disposed on the incline portion so that it is engaged with a slot or aperture defined within a base of the airway bridge. Once in the operating configuration, the patient is laid onto the airway bridge which holds the patient in a position so as to prevent occlusion of the patient's oral airway. CPR may then be performed on the patient. | 2019-08-01 |
20190231643 | VIAL ADAPTER - An exemplary vial adapter may include a moveable member, an elongated member with a first passage, a second passage coupled to an expandable first reservoir, and a third passage coupled to an expandable second reservoir. In a first orientation of an exemplary vial adapter, a fluid may be directed through the first passage into the first reservoir or the second reservoir. In a second orientation of an exemplary vial adapter, a fluid may be drawn through the first passage and a fluid drawn through an air passage into the second passage. In a second orientation of an exemplary vial adapter, a fluid may be directed through the first passage and through the third passage into the second reservoir. In a first orientation of an exemplary vial adapter, a moveable member may be activated to direct a fluid from the second reservoir through the third passage. | 2019-08-01 |
20190231644 | RELAY TRAY - A relay tray for securely transporting items includes a lockable transportable container for holding items to be transported, and an electronic controller including a processor. The relay tray receives electric power through a power interface, and includes a commination interface through which the controller can communicate electronically. The relay tray includes a mechanism operable under control of the controller to make items in the locked container accessible in response to communications received via the communication interface, the mechanism operable by the controller only when power is being received through the power interface. In some implementations, the power interface includes four electrical contacts on an outside surface of the container for receiving power and a rectifier that produces voltage of a polarity suitable for powering the controller. The power interface may function as the communication interface. | 2019-08-01 |
20190231645 | Systems And Methods For Determining Container Contents, Locations, And Surroundings - Systems and methods are provided for determining whether and/or when a patient is taking his or her medication and, when appropriate, providing reminders and/or alerts to the patient to improve adherence to a medication regimen. In some embodiments, a medication container is provided that includes a capacitance sensor for sensing the contents of the medication container (e.g., pill count or quantity of liquid medication). The capacitance sensor may include interleaved or interdigitated electrodes oriented vertically, horizontally, or angularly (e.g., diagonally) relative to an axis of the medication container. Reminders and/or alerts to the patient may be triggered based at least in part on the contents of the medication container, when a cap of the container was last opened and/or closed, the location of the medication container, and/or the container's surroundings. | 2019-08-01 |
20190231646 | Apparatus for Holding Baby Bottles - An apparatus is utilized to position and hold a baby bottle on a chest and/or stomach of an infant. Apparatus includes a body having a front section, a first sidewall, a second sidewall opposite the first sidewall, and a bottom section. A channel positioned within the body and extending through the front section is utilized for receiving a baby bottle. The channel is positioned at an angle in relation to the bottom section in order to properly position the baby bottle in relation to an infant's mouth. | 2019-08-01 |
20190231647 | ENTERAL FEEDING TUBE WITH INFLATABLE CUFF - The enteral feeding tube ( | 2019-08-01 |
20190231648 | DENTAL COMPOSITION COMPRISING A DENTAL FILLER CONTAINING A STRUCTURAL FILLER AND SILANATED GLASS FLAKES - The present invention relates to a dental composition comprising a dental filler containing a structural filler and silanated glass flakes. Furthermore, the present invention relates to the use of silanated glass flakes for preparing a dental composition. | 2019-08-01 |
20190231649 | METHODS AND KITS FOR REMOVING CALCULUS USING A METAL ION AND BICARBONATE - Methods and kits for removing calculus from a tooth, wherein the method can include applying a component A to the tooth, wherein component A comprises: a metal ion selected from the group of lithium ion, magnesium ion, calcium ion, a precursor thereto, and a combination thereof; and an aprotic base having a pKb in water of greater than 15.4, or a precursor thereto; applying a component B to the tooth, wherein component B comprises a bicarbonate ion or a precursor thereto; wherein components A and B are applied simultaneously or sequentially to the tooth, thereby generating a gas to soften and/or loosen at least part of the calculus on the tooth; and removing at least a part of the calculus from the tooth. | 2019-08-01 |
20190231650 | LIGHT-TRANSMISSIVE ZIRCONIA SINTERED BODY AND PREPARATION METHOD THEREFOR AND USE THEREOF - Provided is a light-transmissive zirconia sintered body, obtained by preparing a green body from a powder for the light-transmissive zirconia sintered body by means of isostatic pressing, and sintering the green body at a high temperature and normal pressure after degreasing and biscuit firing. The light-transmissive zirconia sintered body is prepared by dispersing zirconia powder in water, adding an appropriate amount of a dispersant and a binder, mixing the mixture to form a slurry, and spray-granulating same, wherein the molar percentage of yttrium oxide in the zirconia powder is 3-5%. The light-transmissive zirconia sintered body can be used for preparing a fixed dental prosthesis. | 2019-08-01 |
20190231651 | ZIRCONIA COMPOSITION, PARTIALLY SINTERED MATERIAL AND SINTERED MATERIAL AND METHODS FOR PRODUCTION THEREOF, AND LAMINATE - A composition includes granules in which zirconia particles are aggregated. The granules have an average circularity of 0.81 or greater based on a projected image. Additionally, a layered body includes a first layer and a second layer that comprise granules and are adjacent to each other. The granules in the first layer have an average circularity of 0.70 or smaller based on a projected image. The granules in the second layer have an average circularity of 0.92 or greater based on a projected image. | 2019-08-01 |
20190231652 | METHOD FOR PREPARING STICK-TYPE COSMETIC COMPOSITION - A method of preparing a stable stick-type cosmetic composition includes separately stabilizing a clay mineral dispersion and a moisturizing component, thereby uniformly dispersing components in the composition. In a typical stick-type composition, components are not uniformly dispersed, and thus a stick formulation prepared using the same is easily broken upon external impact or the like, but the stick formulation prepared by the method of the present invention is maintained in spreadability and sensation of use, and is not easily broken. | 2019-08-01 |
20190231653 | Skin Care Fabric - A skin care fabric for medical, pharmaceutical or cosmetic use includes at least 80% by weight of microfibers that are a mixture of polyamide and polyester and have a diameter of less than 50 microns. Each microfiber is split to produce fine fibers closely packed in a parallel structure having a capillary effect and an abrasive effect. The fabric has a surface weight of less than 180 g/m | 2019-08-01 |
20190231654 | Sunscreen Sheet - The present disclosure relates to a cosmetic or dermatological sheet impregnated with a sunscreen fluid cosmetic composition. Specifically, the present disclosure relates to a cosmetic or dermatological sheet impregnated with a sunscreen fluid cosmetic composition and method to apply sunscreen to the human user's back or entire body. The sheet may have stitching and other composition or structural aspects to increase the structural integrity, hand slits, mitts or finger holes in the fabric, and/or areas that are not impregnated with a sunscreen composition to enable the user to more easily or tightly grasp the sheet during application of the sunscreen composition. Additionally, the sheet may be used to apply sunscreen to the user's back or entire body more than once before discarding the sheet and may include or consist of dyes, paints, tints or emboss to change the color or design of the sheet. | 2019-08-01 |
20190231655 | COMPOSITE PARTICLES INCLUDING ANIONIC POLYMER AND CATIONIC POLYMER OR PEPTIDE, AND METHOD FOR PRODUCING COMPOSITE PARTICLES - A first problem is to provide a novel technique for forming hyaluronan into particles. Further, a second problem is to provide a novel technique suitable for production of a composite particle containing an anionic polymer and a peptide. | 2019-08-01 |
20190231656 | METHOD OF PROTECTING KERATIN MATERIALS FROM POLLUTANTS - The present invention relates to a non-therapeutic method, preferably a cosmetic method, of protecting keratin materials from pollutants, comprising: applying the keratin materials with at least one composition, preferably at least one cosmetic composition, comprising at least one particle having a wet point for oil being at least 100 ml/100 g, preferably at least 150 ml/100 g, and more preferably at least 200 ml/100 g, and a wet point for water being at least 100 ml/100 g, preferably at least 200 ml/100 g, and more preferably at least 300 ml/100 g. The present invention also relates to the use of the particle or the composition, and the like. The present invention can provide a method or process of protecting keratin materials from pollutants, as well as an anti-pollution agent and a use for the method or process. | 2019-08-01 |
20190231657 | SALICYLIC ACID GEL - A salicylic acid gel contains salicylic acid, a thickener, and a stabilizer compound. The gel may be diluted and/or incorporated into final skin care products. | 2019-08-01 |
20190231658 | STABLE MICROCAPSULE COMPOSITIONS - Disclosed are stable microcapsule compositions each containing a microcapsule dispersed in an aqueous phase and a stabilizing agent. The microcapsule compositions are stable for at least 4 weeks when storing at 45 ° C., and the microcapsule composition is considered stable when (i) the composition has a viscosity of 3000 cP or less and (ii) 20% or less water by volume of the composition is separated from the composition. Also disclosed are consumer products having such a stable microcapsule composition. | 2019-08-01 |
20190231659 | SPHERICAL MICROPARTICLES - The present invention relates to compositions of spherical microparticles composed of a wall material and at least one cavity that comprises a gas and/or a liquid, which have pores on the surface thereof, wherein the spherical microparticles have a mean particle diameter of 10-600 μm and wherein at least 80% of those microparticles, the particle diameter of which does not deviate from the mean particle diameter of the microparticles of the composition by more than 20%, each have on average at least 10 pores, the diameter of which is in the range from 1/5000 to ⅕ of the mean particle diameter, and, furthermore, the diameter of each of these pores is at least 20 nm, | 2019-08-01 |
20190231660 | HYDROGEN SUPPLY MATERIAL AND PRODUCTION THEREFOR, AND HYDROGEN SUPPLY METHOD - A layered solid formulation ( | 2019-08-01 |
20190231661 | Heterogenous Cosmetic Ink Composition For Inkjet Printing Applications - A cosmetic ink composition comprises a particulate material, a polymeric dispersant having a weight average molecular weight of less than about 20,000 daltons, and a polymeric rheology modifier. The particulate material can have a Particle Size Distribution D50 of about 100 nm to about 2,000 nm. The cosmetic ink composition can undergo controlled syneresis, forming a weak colloidal gel phase and a particle-lean, low viscosity phase, which can be printed without interventions such as agitation, mixing, or re-circulation to homogenize the composition. | 2019-08-01 |
20190231662 | Cosmetic Ink Composition Comprising A Surface Tension Modifier - A cosmetic ink composition comprises a particulate material, a polymeric dispersant, a rheology modifier, and a surface tension modifier, wherein the surface tension modifier is selected from the group consisting of C1-C16 alcohols, C5-C18 diols, and mixtures thereof. The particulate material can have a Particle Size Distribution D50 of about 100 nm to about 2,000 nm. The rheology modifier can be selected from the group consisting of alkali swellable emulsion polymers, hydrophobically modified alkali swellable emulsion polymers, and combinations thereof. The cosmetic ink composition can have a surface tension of from about 20 to about 45 mN/m. | 2019-08-01 |
20190231663 | COOLING GEL COMPOSITION - The present invention relates to a cooling gel composition comprising methyl diisopropyl propionamide, at least one C2-C5 alcohol, at least one silica aerogel and at least one powder, as well as to systems and methods for making-up and enhancing the appearance of keratinous materials using the cooling gel composition. | 2019-08-01 |
20190231664 | COSMETIC COMPOSITIONS FOR COMBATTING COLOUR LOSS FROM A DYED MATERIAL - A concentrate composition comprising: (a) at least 0.1 wt % of a surfactant compound; and (b) at least 10 wt % one or more ingredients selected from aldehydes, succinimidyl esters, chelating agents and amine salts of carboxylic acids. | 2019-08-01 |
20190231665 | HAIR COSMETIC COMPOSITIONS CONTAINING THIOL-BASED COMPOUNDS AND METHODS FOR CLEANSING AND TREATING HAIR - The present invention relates to a hair cosmetic composition for cleansing and conditioning hair fibers, in particular human hair fibers, the hair cosmetic composition comprising anionic surfactants, amphoteric surfactants, thiol-based compounds selected from thiolactic acid, thiolactic acid derivatives, their salts, and mixtures thereof, thickening agents; nonionic surfactants; and water; wherein the pH of the composition ranges from about 2 to less than 7. The invention also concerns a method for imparting hair care benefits to hair fibers such as straightening effects, volume reduction, frizz control, manageability, cosmeticity, and smooth feel, in addition to cleansing and conditioning benefits and a use for hair care employing the cosmetic compositions of the present invention. | 2019-08-01 |
20190231666 | ANTI-DANDRUFF COMPOSITION - Disclosed is use of myricetin and/or a derivative of myricetin as an active anti-dandruff agent in a composition for topical application to the scalp and/or hair. | 2019-08-01 |
20190231667 | Oral Care Compositions and Methods of Use - Disclosed herein are oral care compositions comprising naringin:Zinc complexes having a 2:1 naringin to zinc molar ratio. Methods of making and using the compositions are also provided. | 2019-08-01 |
20190231668 | SKIN WHITENING COMPOSITION CONTAINING MANNOSYLERYTHRITOL LIPID - The present invention relates to a skin whitening composition containing mannosylerythritol lipid (MEL) as an active ingredient. The skin whitening composition according to the present invention suppresses the formation of skin melanocytes and improves the overall skin tone, and thus gives effectiveness of exhibiting clean, darkness-relieved, and bright skin. In addition, the composition can be easily formulated, and thus can be utilized in a high content for various dosage forms even without using a particular additional ingredient for formulating effective ingredient. | 2019-08-01 |
20190231669 | COSMETIC COMPOSITIONS - The present invention relates to cosmetic compositions comprising at least one inorganic micropigment, characterized in that said cosmetic compositions are substantially free of any C | 2019-08-01 |
20190231670 | TOPICAL COMPOSITION - A topical composition comprising at least one retinoid, alfalfa extract, and at least one carrier and uses thereof. | 2019-08-01 |
20190231671 | Stable Cosmetic Ink Composition - A cosmetic ink composition comprises a particulate material, a (meth)acrylic acid homopolymer or salt thereof, and a rheology modifier. The particulate material can have a Particle Size Distribution D50 of about 100 nm to about 2,000 nm. The (meth)acrylic acid homopolymer or salt thereof can have a weight average molecular weight of less than about 20,000 daltons. The rheology modifier can be selected from the group consisting of alkali swellable emulsion polymers, hydrophobically modified alkali swellable emulsion polymers, and combinations thereof. The cosmetic ink composition can have a first dynamic viscosity of greater than about 1,100 cP at a shear rate of 0.1 sec | 2019-08-01 |
20190231672 | PERSONAL CLEANSING COMPOSITIONS - The invention provides a personal cleansing composition comprising: (i) an aqueous continuous phase including cleansing surfactant; (ii) one or more oily liquid conditioning agents for skin and/or hair wherein the agent is solubilized in wormlike micelles in the aqueous continuous phase via the incorporation of at least one inorganic electrolyte and at least one linker molecule; (iii) one or more cationic deposition polymers which are selected from cationic polygalactomannans having a mean charge density at pH7 from 0.2 to 2 meq per 10 gram; and (iv) a hair substantive cationic conditioning polymer which is a homopolymer of (3-acrylamidopropyl) trimethyl ammonium chloride. | 2019-08-01 |
20190231673 | MAKE UP KIT COMPRISING A BASE COMPOSITION RESISTANT TO MAKE- UP REMOVAL - The present invention relates to a kit for make-up and/or care of nails and/or false nails, comprising:
| 2019-08-01 |
20190231674 | NOVEL RESIN-LINEAR ORGANOPOLYSILOXANE BLOCK COPOLYMER, USE OF SAME, AND METHOD FOR PRODUCING SAME - Provided is a resin-linear organopolysiloxane block copolymer which has a high degree of freedom in formulation due to excellent compatibility with other materials, in addition to exhibiting excellent film forming properties and followability of a film, while the stickiness of a film is suppressed. The resin-linear organopolysiloxane block copolymer has: a resin structure (A1) block that has siloxane units represented by R | 2019-08-01 |
20190231675 | TOPICAL COSMETIC COMPOSITIONS - Disclosed are compositions and methods for their use for reducing tumor necrosis factor alpha (TNF-α) and/or vascular endothelial growth factor (VEGF) production in skin cells by topically applying to skin in need thereof, a composition comprising an effective amount of | 2019-08-01 |
20190231676 | BODY BUTTER AND METHOD OF MANUFACTURE - A body butter that includes a base oil, beeswax, shea butter, cocoa butter, and vitamin E oil. | 2019-08-01 |
20190231677 | TOPICAL COMPOSITIONS - The present invention relates generally to compositions for a topical composition comprising | 2019-08-01 |
20190231678 | Compositions Comprising Antioxidant, Fluid Dispensers, and Methods Involving the Same - A composition includes a salt; a polymer; and an antioxidant. A dispenser includes a flexible container having a closed end and an opposed open end; an osmotically-effective solute composition encapsulating at least a portion of the container, the solute composition including antioxidant in an amount of at least 0.5 wt %, based on weight of the solute composition; a semipermeable membrane encapsulating the osmotically-effective solute composition; a cap having a sealing surface adapted for sealing engagement with the open end of the container; and a port extending from an interior of the container and through the cap. Also disclosed are methods of making and using the composition and osmotic pumps. | 2019-08-01 |
20190231679 | METHODS FOR ADMINISTERING ARIPIPRAZOLE - The present invention relates, in part, to the discovery that a pharmaceutical composition comprising aripiprazole and a carrier administered in a bolus injection resulted in an extended release profile similar to that obtained by the injection of a poly lactide-co-glycolide microsphere formulation containing the active agent. This surprising result suggests that pharmacologically beneficial extended release formulations without the complexities and expense associated with the manufacture microspheres. | 2019-08-01 |
20190231680 | INTRAVENOUS ADMINISTRATION OF TRAMADOL - A method of treating pain, e.g., acute post-operative pain, by intravenously administering to a human patient(s) a dose of tramadol of about 45 mg to about 80 mg, based on tramadol hydrochloride, together with an intravenous dose of acetaminophen in an amount from about 500 mg to about 1000 mg, about every 6 hours. | 2019-08-01 |
20190231681 | INTRAVENOUS ADMINISTRATION OF TRAMADOL - A method of treating pain, e.g., acute post-operative pain, by intravenously administering to a human patient(s) a dose of tramadol of about 45 mg to about 80 mg, based on tramadol hydrochloride, together with an intravenous dose of a therapeutically effective amount of ketorolac about every 6 hours. | 2019-08-01 |
20190231682 | INJECTABLE COMPOSITION WITH AROMATASE INHIBITOR - The present invention provides a composition suitable for forming an intramuscular implant. It comprises a biodegradable thermoplastic polymer of polylactic acid (PLA), DMSO and an aromatase inhibitor compound. The invention also provides a kit suitable for the in situ formation of the composition and its use as a medicine for treating cancer, especially breast cancer. | 2019-08-01 |
20190231683 | Applicators for treating vaginal dryness - A kit for treating vaginal dryness is provided. The kit comprises a hand held applicator and a dispenser or receptacle storing a vaginal care composition. | 2019-08-01 |
20190231684 | TEAT PACK MATERIAL FOR LACTATING LIVESTOCK, KIT FOR FORMING TEAT PACK FOR LACTATING LIVESTOCK, AND METHOD FOR PREVENTING MASTITIS IN LACTATING LIVESTOCK - A method for preventing mastitis in lactating livestock includes forming a teat pack for the lactating livestock by adhering one of (i) a base comprising at least (A) a polymer latex and (ii) a secondary agent comprising at least (B) a coagulant to a teat of the lactating livestock, and subsequently adhering the other to the teat. | 2019-08-01 |
20190231685 | ANTIHISTAMINE ORAL FILM DOSAGE FORM AND METHOD OF ADMINISTRATING SAME - An oral film dosage form for administration in the buccal cavity includes a film layer containing a safe and effective amount of an antihistamine and 3% to 12% (w/w) of a numbness mitigating agent. | 2019-08-01 |
20190231686 | METHODS FOR TREATING CYSTIC FIBROSIS AND OTHER DISEASES AFFECTING MUCOSAL SURFACES - A method of treating and/or managing cystic fibrosis (CF) and/or other infectious or inflammatory lung disease or mucosal surface condition in a patient in need thereof, using a drug formulation with beneficial and/or synergistic effects among ingredients which comprise the formulation herein reported. Cystic fibrosis disease is characterized by loss of homeostatic balance at mucosal surfaces, resulting in persistent infection, excessive sticky mucus and tissue-destructive host inflammatory responses. When used to treat lung disease, this invention is delivered to airways as an inhaled dose by nebulizer. The formulation(s) arising from this invention are preferably composed of natural endogenous compounds already found within the body but possibly obtained from other sources, and/or of plant phytochemicals, which in combinations herein disclosed, have synergistic hydrating, anti-inflammatory and antimicrobial properties as well as direct corrector and/or potentiator effects and/or other modulating effects on CFTR function when administered to mucosal surface where CFTR with some residual function is achieved. Synthetic molecules can also be used. | 2019-08-01 |
20190231687 | ENDOXIFEN METHODS AND COMPOSITIONS IN THE TREATMENT OF PSYCHIATRIC AND NEURODEGENERATIVE DISEASES - The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of a subject having or at risk for psychiatric and neurodegenerative diseases. Specifically, the present invention relates to the composition comprising endoxifen in the treatment of bipolar disorder, schizophrenia, multiple sclerosis (MS), Alzheimer disease, Parkinson disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), and/or epilepsy by administrating formulations or compositions comprising an effective amount of endoxifen. | 2019-08-01 |
20190231688 | METHOD OF ADMINISTERING EMULSION FORMULATIONS OF AN NK-1 RECEPTOR ANTAGONIST - Disclosed herein are methods of administering pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist to a subject in need of treatment of emesis. | 2019-08-01 |
20190231689 | Amphiphilic Block Copolymer Composition With Enhanced Micelle Stability - A composition comprising an A-B type diblock copolymer or a B-A-B or A-B-A type triblock copolymer with enhanced micelle stability, wherein A is a hydrophilic block and B is a hydrophobic block, and a polymeric micelle composition, a drug carrier composition and a pharmaceutical composition comprising the same are provided. | 2019-08-01 |
20190231690 | PLATINUM COMPLEXES AND USES THEREOF - The disclosure generally relates to compositions comprising therapeutic agent complexes and to methods of making and using the compositions. In particular embodiments, the disclosure provides compositions comprising platinum-based drug complexes and to methods of making and using these compositions. | 2019-08-01 |
20190231691 | Biopharma Application Of Micell Technology - Drug delivery systems are disclosed which include a drug in dry powder form and a biodegradable or metabolizable carrier having an average particle size of less than about 1 mm for delivery of the drug to a particular location in the body and for providing for the timed elution of the drug at that location, preferably by exhibiting a linear drug elution profile for a sustained drug release period of at least 30 days. Methods for manufacturing these drug delivery systems are also disclosed. | 2019-08-01 |
20190231692 | SYSTEM AND METHOD FOR ISOLATING EXTRACELLULAR VESICLES - A system and method of isolating extracellular vesicles. The method includes loading one or more of blood or bone marrow into an input port of a concentration system and centrifuging one or more of the blood or bone marrow to separate one or more of red blood cells, platelet poor plasma, or platelet rich plasma/bone marrow concentrate fractions via a centrifuge device. The method further includes pumping one or more of bone marrow/platelet rich plasma fractions and platelet poor plasma fractions into a receptacle of the concentration system and adding a concentrated aqueous two-phase solution to one or more of the bone marrow concentrate/platelet rich plasma fractions and platelet poor plasma fractions. The method also includes drawing the concentrated aqueous two-phase solution and one or more of the bone marrow concentrate/platelet rich plasma fractions or platelet poor plasma fractions back into the centrifuge device to isolate one or more of extracellular vesicles and platelet rich plasma/bone marrow concentrate fractions. | 2019-08-01 |
20190231693 | LYOPHILIZED FORMULATION OF TAT-NR2B9C WITH ACETYLATION SCAVENGER - The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c including histidine, trehalose and lysine. TAT-NR2B9c has shown promise for treating stroke, aneurysm, subarachnoid hemorrhage and other neurological or neurotraumatic conditions. Such formulations are stable at ambient temperature thus facilitating maintenance of supplies of such a formulation in ambulances for administration at the scene of illness or accident or in transit to a hospital. | 2019-08-01 |
20190231694 | METHOD FOR LYOPHILISING AN EXOSOME - The invention concerns a method for lyophilising exosomes by providing an exosome suspension in a lyophilisation buffer comprising a sugar at less than 10% w/v. The method is to preserve exosomes structural and biochemical integrity as well as the therapeutic efficacy for long term storage at ambient temperature. In one embodiment, the lyophilisation buffer comprises trehalose at 4% w/v. In another embodiment, removal of water from the frozen suspension deposits the exosomes on a biocompatible scaffold. | 2019-08-01 |
20190231695 | COMPOSITIONS AND METHODS FOR NANOPARTICLE LYOPHILE FORMS - This invention provides compositions for making a solid lyophile of one or more nucleic acid active agents, which can be reconstituted as a drug product. The composition can include an aqueous suspension of lipid nanoparticles in a pharmaceutically acceptable solution, wherein the lipid nanoparticles encapsulate one or more nucleic acid active agents, a dextrin compound, and a saccharide compound. The nucleic acid active agents can be RNAi molecules capable of mediating RNA interference, as well as other RNAs and oligonucleotides. | 2019-08-01 |
20190231696 | SUSTAINED-RELEASE DOSAGE FORMS OF RUXOLITINIB - The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders. | 2019-08-01 |
20190231697 | GASTRIC RESIDENCE SYSTEMS FOR SUSTAINED DELIVERY OF ADAMANTANE-CLASS DRUGS - The invention provides gastric residence systems for administration of adamantane-class drugs or pharmaceutically acceptable salts thereof, such as memantine or pharmaceutically acceptable salts thereof, and methods for making and using such systems. The systems provide extended release of drug, reducing the frequency with which the drug must be administered to the patient. The gastric residence systems, or components of gastric residence system such as segments or elongate members of gastric residence systems, can have release rate-modulating films, which provide good control over release of adamantane-class drugs or pharmaceutically acceptable salts thereof present in the gastric residence system. Some embodiments of the films can provide resistance against burst release of adamantane-class drugs or pharmaceutically acceptable salts thereof upon exposure to alcohol. | 2019-08-01 |
20190231699 | CONTROLLED-RELEASE SOLID DOSAGE FORMS OF MESALAMINE - Described are controlled-release solid dosage forms of mesalamine. In one aspect of the invention the controlled-released solid dosage forms of mesalamine are capsules comprising a plurality of coated mini-tablets. Another aspect of the invention related to a methods of treating a patient suffering from inflammatory bowel disease, comprising the step of administering to the patient a therapeutically effective amount of the solid dosage form. The invention also relates to methods of inducing remission of inflammatory bowl disease and maintaining remission of inflammatory bowel disease. In certain aspects, the inflammatory bowel disease is ulcerative colitis or Crohn's disease. | 2019-08-01 |
20190231700 | ORALLY DISINTEGRATING TABLET COATED WITH FILM - Provided is an orally disintegrating tablet film-coated with a composition for film coating containing hypromellose and hydroxypropyl cellulose but not containing a plasticizer. | 2019-08-01 |
20190231701 | Fill formulation method for hard, soft, and liquid capsules comprising the mixture of a polymer and a fill component that will migrate into or through a capsule shell with serviceable functions - The present disclosure described is a fill formulation method for hard, soft, and liquid capsules comprising a polymer and a fill component, wherein the polymer comprised of mycoprotein is mixed with a fill component mixture comprised of a plasticizing agent, a preservative agent, a lubricant agent, and purified water, which will migrate into or through a capsule shell, with attributes of serviceable functions. | 2019-08-01 |
20190231703 | HYDROPHILIC NANOSTRUCTURED MEMBRANE ACTIVE ANTIMICROBIALS WITH HIGH ACTIVITY, SELECTIVITY AND BIODEGRADABILITY - The present invention includes compositions and methods of making hydrophilic nanostructured antibiotics (i.e. nanoantibiotics), including nanoantibiotics that use environmentally degradable biomolecules as the backbone building blocks, wherein the backbone building blocks can include spherical backbones such as sucroses, cyclodextrins, glycogens, and phytoglycogen with different diameters, or rod-like backbone building blocks such as dextrins, amyloses, and celluloses with different lengths. These hydrophilic nanoantibiotics with well-defined sizes and shapes can selectively disrupt bacterial membranes (i.e., serve as membrane-active antimicrobials) while being benign to mammalian cells. Depending on the size and shape difference of the hydrophilic nanoantibiotics, they can also selectively kill one type of bacteria (e.g., gram-negative) over another type (e.g., gram-positive). The environmentally degradable nanoantibiotics will have built-in dismantling “switches” to dismantle and become antimicrobial inactive in responsive to environmental stimuli once released into natural habitat, hence greatly reducing the possibility of developing bacteria resistance. | 2019-08-01 |
20190231704 | COMPOSITIONS FOR ENHANCED UPTAKE BY MACROPHAGES AND METHODS OF USE THEREOF - Negatively charged nanoparticulate compositions are used to deliver therapeutic, prophylactic or diagnostic agents to macrophages or other phagocytic cells in the brain and central nervous system. The negative charge of the nanoparticles increases circulation, increases internalization by macrophage or other phagocytic cells, increases release within the macrophage or other phagocytic cells, or a combination thereof, relative to charge-neutral or charge-positive nanoparticles. | 2019-08-01 |
20190231705 | HIGH DRUG LOAD POLYMERIC NANOPARTICLE FORMULATIONS AND METHODS OF MAKING AND USING SAME - Described herein are polymeric nanoparticles that comprise {[(1R,25)-1-({[(1aR,5S,8S,10R,22aR)-5-tert-butyl-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]-dioxadiazacyclo-nonadecino[11,12-b]quinoxalin-8-yl]carbonyl}amino)-2-vinylcylopropyl]carbonyl}(cyclopropylsulfonyl)azanide, (i.e., grazoprevir), or a pharmaceutically acceptable salt thereof, and methods of making and using such nanoparticles. | 2019-08-01 |
20190231706 | SURFACTANT PEPTIDE NANOSTRUCTURES AND USES IN DRUG DELIVERY - Disclosed herein are surfactant peptide nanostructures wherein the peptides have repeating hydrophobic amino acids in an integer equal to or less than four. The peptide nanostructures are useful for therapeutic applications, including for delivery of drugs and siRNA. | 2019-08-01 |
20190231708 | WATER-BASED ADHESIVE PATCH - The present invention provides an aqueous patch which can stably contain only one of an S-enantiomer and an R-enantiomer of a drug capable of being present in such enantiomers at a relatively high concentration over a long period of time, has the excellent adhesive property and the excellent shape retaining property, and achieves high skin permeability of the drug. Specifically, the present invention provides an aqueous patch containing only one of enantiomers of a drug as an active ingredient in a pasty preparation. | 2019-08-01 |
20190231709 | ADHESIVE MATRIX WITH HYDROPHILIC AND HYDROPHOBIC DOMAINS AND A THERAPEUTIC AGENT - An adhesive matrix and adhesive formulation are described. The adhesive matrix is comprised of a hydrophilic domain and a hydrophobic domain, and a therapeutically active agent contained in the matrix in a supersaturated, stable, condition. The hydrophilic domain and the hydrophobic domain are co-soluble in a solvent system, to provide a homogeneous blend in which the active agent is solubilized. The proportion of the hydrophilic domain and hydrophobic domain is selected to optimize, or maximize, solubility of active agent in the matrix. | 2019-08-01 |
20190231710 | TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING ACTIVE INGREDIENT PARTICLES AND HAVING INCREASED ACTIVE INGREDIENT FLUX - The present invention relates to a transdermal therapeutic system, preferably a transdermal patch, having an active ingredient-containing matrix formed substantially of a water-insoluble base material, such as rubber and synthetic polymers, into which is incorporated water-soluble and/or water-swellable inclusion bodies, e.g. inclusion bodies formed from polyvinyl alcohol or polyethylene glycol, that further include micronized or nanoscale active ingredient particles. | 2019-08-01 |
20190231711 | Dihydromyricetin Compositions - The disclosure provides dermal patch formulations that include a pharmaceutically active agent, such as one or more cannabinoids. The formulations can include dihydromyricetin for the purpose of increasing the flux of the pharmaceutical agent into human skin. | 2019-08-01 |
20190231712 | TRANSDERMAL ABSORPTION PREPARATION - Provided is a transdermal absorption preparation having superior drug skin permeability, which can uniformly disperse the drug in the preparation and maintain the uniform dispersion state of the drug. | 2019-08-01 |
20190231713 | METHODS FOR TREATING OR PREVENTING ORGANOPHOSPHATE POISONING - The invention relates to methods of treating or preventing organophosphate poisoning in a subject in need thereof, comprising administering to the subject isoflurane, enflurane, halothane, sevoflurane, desflurane, xenon or argon in a therapeutically effective amount. | 2019-08-01 |
20190231714 | EMESIS TREATMENT - A composition for the treatment of emesis comprising 8-hydroxy-2-(dipropylamino)tetralin in which the ratio of the S enantiomer of the 8-hydroxy-2-(dipropylamino)tetralin to the R enantiomer of the 8-hydroxy-2-(dipropylamino)tetralin is between 2:1 and 10:1, and a method of treating or preventing emesis with such a composition. | 2019-08-01 |
20190231715 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT - The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE. | 2019-08-01 |
20190231716 | Epinephrine Nanoparticles, Methods of Fabrication Thereof, And Methods for Use Thereof for Treatment of Conditions Responsive to Epinephrine - The invention provides compositions including epinephrine nanoparticles and methods for therapeutic use of the compositions for the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions. | 2019-08-01 |
20190231717 | ENERGY DRINKS AND OTHER NUTRITIONAL AIDS DERIVED FROM AGAVE-BASED SPIRITS - Compositions containing monoamine oxidase inhibitors prepared by removal of alcohol from agave-derived beverages are disclosed. | 2019-08-01 |
20190231718 | TREATMENT OF BREAST CANCER - The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women, and in particular embodiments, methods for treating ER+ cancers having gain of function mutations in the ESR1 ligand binding domain, with an effective amount of a compound selected from the group consisting of raloxifene, bazedoxifene, tamoxifen, etacstil, and fulvestrant, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers. | 2019-08-01 |
20190231720 | ALDH2 ACTIVATOR - The present invention provides a compound represented by formula ( | 2019-08-01 |
20190231721 | SULFONAMIDE PHARMACEUTICAL COMPOSITION - A sulfonamide pharmaceutical composition. The present invention relates to a sulfonamide compound injectable preparation comprising a sulfonamide compound or a derivative thereof. The injectable preparation is prepared from the sulfonamide compound and a pharmaceutically acceptable carrier through certain preparation technologies. The sulfonamide compound injectable preparation involved in the present invention is stable and controllable in quality and effective. | 2019-08-01 |
20190231722 | INHALATION FORMULATIONS OF TREPROSTINIL - The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof. | 2019-08-01 |
20190231723 | COMPOUNDED COMPOSITIONS AND METHODS FOR TREATING PAIN - A method of compounding a topical composition includes combining lidocaine and prilocaine, 2.5%/2.5%, cream, diclofenac sodium, 1.5%, topical solution, lidocaine hydrochloride, 4%, topical solution, diclofenac sodium USP powder, lidocaine hydrochloride USP monohydrate powder, and prilocaine hydrochloride USP powder and mixing to generate a cream. | 2019-08-01 |
20190231724 | THERAPEUTIC AGENT FOR GLAUCOMA - Provided is a novel therapeutic agent for glaucoma, which has sGC-activating action. A therapeutic agent for glaucoma or an ocular hypotensive agent, which contains, as an effective component, a compound represented by Formula (I-a) or Formula (I-b) and having a LogD value of more than 1.5 and less than 2.5, or a pharmaceutically acceptable salt thereof. [In formulae (I-a) and (I-b), each symbol is as defined in the description.] | 2019-08-01 |
20190231725 | Compositions and Methods for Treatment of Diabetic Neuropathies - The invention provides compositions and methods to treat diabetic neuropathies. In particular, the invention provides combinations of at least two types of antioxidants have complementary effects for use against diabetic neuropathies. The two types of antioxidants include: antioxidants that comprise stabilizing heteroatoms and antioxidants with extended conjugated segments in a ring structure. At least one of each type of provided antioxidant has a pro-oxidative or conditionally pro-oxidative effect. | 2019-08-01 |
20190231726 | TREATMENT OF NERVOUS SYSTEM DISORDERS USING COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES - Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone. | 2019-08-01 |
20190231727 | COMPOSITIONS COMPRISING RUMENIC ACID-RICH CONJUGATED LINOLEIC ACID FOR JOINT HEALTH - Methods for enhancing joint function and for treating or preventing age-related joint discomfort in an adult human are disclosed. The methods comprise administering to the human a dietetic food, medical food, or food supplement. The food or food supplement comprises a rumenic acid-rich conjugated linoleic acid (RAR-CLA), or a pharmaceutically acceptable salt, ester, mono-, di-, or triglyceride, metabolic precursor thereof, or mixture thereof, in an amount effective to enhance joint function or to alleviate joint discomfort in the human. The RAR-CLA comprises cis-9, trans-11 linoleic acid and trans-10, cis-12 linoleic acid isomers in a weight ratio of at least 2:1. Enrichment of a dietetic food, medical food, or food supplement with RAR-CLA can help to improve joint function and/or alleviate joint discomfort. Longer-term studies should help to further elucidate the potential impact of RAR-CLA supplementation on joint function in older adults. | 2019-08-01 |
20190231728 | BENZOQUINONE DERIVATIVE E3330 IN COMBINATION WITH CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER AND ANGIOGENESIS - Disclosed are novel methods for the therapeutic treatment of cancer and angiogenesis. The enzyme Ape1/Ref-1, via its redox function, enhances the DNA binding activity of transcription factors that are associated with the progression of cancer. The present invention describes the use of agents to selectively inhibit the redox function of Ape1/Ref-1 and thereby reduce tumor cell growth, survival, migration and metastasis. In addition, Ape1/Ref-1 inhibitory activity is shown to augment the therapeutic effects of other therapeutics and protect normal cells against toxicity. Further, Ape1/Ref-1 inhibition is shown to decrease angiogenesis, for use in the treatment of cancer as well other pathologic conditions of which altered angiogenesis is a component. | 2019-08-01 |
20190231729 | DISORDERS IMPLICATING PUFA OXIDATION - Some aspects of the invention provide for a method of treating hepatic disorders, lipidemias and cardiac-related risk factors using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and/or suppress the rate of formation of reactive products and toxic compounds. | 2019-08-01 |
20190231730 | TREATMENT OF A DISEASE MEDIATED BY ARACHIDONIC ACID OR AN EICOSANOID - Disclosed is a method of treating a disease mediated by arachidonic acid or an eicosanoid. The method includes administering to a subject in need thereof an effective amount of an analogue of arachidonic acid or an analogue of eicosanoid. The analogue is a dehydro-analogue of an arachidonic acid, HPETE, EET, a prostaglandin or HETE. Diseases that may be treated include cancer, ischemic heart disease, psoriasis, cystic fibrosis, Alzheimer's disease, allergy, COPD, rheumatoid arthritis (RA), ulcerative colitis, or Crohn's disease. | 2019-08-01 |
20190231731 | SELF-EMULSIFYING COMPOSITION OF OMEGA3 FATTY ACID - A self-emulsifying composition contains: 70 to 90% by weight in total of one or more compounds selected from the group consisting of ω3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 1 to 29% by weight of an emulsifying agent selected from among a polyoxyethylene sorbitan fatty acid ester, a sorbitan fatty acid ester, a glycerin fatty acid ester and a polyoxyl castor oil; and 0.5 to 6% by weight of water when the composition is defined to be 100% by weight as a whole. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals. | 2019-08-01 |
20190231732 | COMPOSITIONS AND METHODS FOR STIMULATING VENTILATORY AND/OR RESPIRATORY DRIVE - A method of stimulating ventilatory and/or respiratory drive in a subject in need thereof includes administering to the subject a therapeutically effective amount of a composition comprising a cystine ester or a pharmaceutically acceptable salt thereof. | 2019-08-01 |
20190231733 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS - Some aspects of the invention provide for a method of treating Alzheimer's Disease, Mild Cognitive Impairment, Frontotemperal Dementia, Amyotrophic Lateral Sclerosis and/or Multiple Sclerosis using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and/or suppress the rate of formation of reactive products and toxic compounds. | 2019-08-01 |
20190231734 | Doxepin Isomers And Isomeric Mixtures And Methods Of Using The Same To Treat Sleep Disorders - The invention relates to use of the cis-(Z) isomer or isomeric mixtures containing specified ratios of the cis-(Z) and trans-(E) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders | 2019-08-01 |
20190231735 | METHODS FOR TREATING CANCER - Methods comprising administration of, and kits comprising, at least one compound of formula (I) | 2019-08-01 |
20190231736 | PREBIOTIC FORMULATION - A method of generating an oligosaccharide encapsulated cannabidiol (CBD) formulation includes forming a cannabidiol ethanol mixture comprising ethanol and cannabidiol, forming an oligosaccharide CBD slurry by mixing the oligosaccharide with the cannabidiol ethanol mixture. The slurry is heated and mixed in a pressurized chamber to form a colloidal mixture, which is distributed into a tray as a layer. A cover is added to the tray to form an evaporation vessel, which is heated in a heating chamber. A rapid cooling process is performed on the colloidal mixture layer by removing the cover and spraying pulverized dry ice on the layer. The rapid cooling process is repeated until crystal formation is detected within the layer, the crystals including oligosaccharide encapsulated cannabidiol. An oligosaccharide encapsulated cannabidiol formulation includes cannabidiol and at least one oligosaccharide in a ratio in the range between about 1000:1 to 2200:1 (w/w) of CBD. | 2019-08-01 |
20190231737 | HEMP POWDER - A mixture of cannabinoids, drying agents, flowing agents, and/or stabilization agents are provided. The mixture may be a dry powder formulation similar to the consistency of flour or sand. The mixture may comprise a cannabinoid raffinate, an isolated cannabinoid, maltodextrin, and or silica. The ratio of raffinate to solids may be less than 0.625. | 2019-08-01 |
20190231738 | Method of maximizing epigallocatechin gallate content in tea - This invention describes a new method to maximize the epigallocatechin gallate (EGCG) content of brewed tea made using leaves and buds from | 2019-08-01 |
20190231739 | NEW USE OF CHROMONE DERIVATIVE AS PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF FIBROSIS USING EMT INHIBITORY ACTIVITY - A pharmaceutical composition contains the chromone derivative of Chemical Formula 1 and a pharmaceutically acceptable salt as an active ingredient, thus effectively inhibiting the activation of EMT to thereby enable the effective suppression of a disease caused by fibrosis of an organ or tissue in vivo due to the activation of EMT. | 2019-08-01 |
20190231740 | BLOOD FLOW-IMPROVING AGENT, ROYAL JELLY COMPOSITION, AND METHOD FOR PRODUCING ROYAL JELLY COMPOSITION - The present invention provides a blood flow-improving agent comprising 10-hydroxydecanoic acid as an active ingredient. | 2019-08-01 |
20190231741 | METHODS OF TREATING DISORDERS WITH GLYCOSYLATION DEFECTIVE PROTEINS - A method of treating a glycosylation-defective protein associated disease or disorder in a subject, the method includes administering to the subject a therapeutically effective amount of a Sarco/ER ATPase (SERCA) inhibitor. | 2019-08-01 |
20190231742 | NUTRITIONAL AGENTS USED TO PREVENT AND TREAT HYPERSENSITIVITY AND OTHER ALLERGIC-TYPE DISORDERS - A nutritional agent that orally delivers a therapeutically effective amount of a ketone body selected from the group consisting of | 2019-08-01 |
20190231743 | LASOFOXIFENE TREATMENT OF VVA AND OSTEOPOROSIS IN SURVIVORS OF BREAST CANCER AND OTHER MALIGNANCIES - The disclosure provides methods for treating vulvovaginal atrophy (WA) and osteoporosis in breast cancer survivors and survivors of other malignancies with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. | 2019-08-01 |
20190231744 | PROTEIN HYDROLYSATES - The present invention provides marine protein hydrolysates for use in pharmaceuticals, nutraceuticals functional foods, foods, beverages, and animal feeds, as well as methods for making marine protein hydrolysates. | 2019-08-01 |